TERN
Terns Pharmaceuticals Inc
$
18.470
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
18.500
Open
18.000
VWAP
17.91
Vol
3.46M
Mkt Cap
1.62B
Low
17.390
Amount
62.05M
EV/EBITDA(TTM)
--
Total Shares
64.68M
EV
1.30B
EV/OCF(TTM)
--
P/S(TTM)
--
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
--
--
-0.310
+19.36%
--
--
-0.306
+27.42%
--
--
-0.300
+7.31%
Estimates Revision
The market is revising No Change the revenue expectations for Terns Pharmaceuticals, Inc. (TERN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 203.78%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.19%
In Past 3 Month
Stock Price
Go Up
+203.78%
In Past 3 Month
10 Analyst Rating
-26.96% Downside
Wall Street analysts forecast TERN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TERN is 13.49 USD with a low forecast of 7.44 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
2 Hold
0 Sell
Strong Buy
-26.96% Downside
Current: 18.470
Low
7.44
Averages
13.49
High
17.00
-26.96% Downside
Current: 18.470
Low
7.44
Averages
13.49
High
17.00
H.C. Wainwright
Andrew Fein
Neutral -> Buy
upgrade
$20
2025-11-04
New
Reason
H.C. Wainwright
Andrew Fein
Price Target
$20
2025-11-04
New
upgrade
Neutral -> Buy
Reason
H.C. Wainwright analyst Andrew Fein upgraded Terns Pharmaceuticals to Buy from Neutral with a $20 price target.
H.C. Wainwright
H.C. Wainwright
Neutral -> Buy
upgrade
$7 -> $20
2025-11-04
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $20
2025-11-04
New
upgrade
Neutral -> Buy
Reason
H.C. Wainwright upgraded Terns Pharmaceuticals to Buy from Neutral with a price target of $20, up from $7. The company reported "compelling" Phase 1 data for TERN-701 in previously treated chronic phase chronic myeloid leukemia. The firm views the data as a "material value inflection: for Terns that elevates the program into a "best-in-disease contender." H.C. Wainwright now sees "credible paths for multi-line relevance," including future front-line positioning, for TERN-701.
BMO Capital
Outperform
maintain
$15 -> $22
2025-11-04
New
Reason
BMO Capital
Price Target
$15 -> $22
2025-11-04
New
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Terns Pharmaceuticals to $22 from $15 and keeps an Outperform rating on the shares. Even following its results, shares may be undervalued with products like Novartis's Scemblix estimated to reach well over $3B in peak sales, the analyst tells investors in a research note. Investor attention now turns to ASH full data and incremental updates in 2026 regarding Phase 3 trial design with FDA, the firm added.
Barclays
NULL -> Overweight
upgrade
$14 -> $27
2025-11-04
New
Reason
Barclays
Price Target
$14 -> $27
2025-11-04
New
upgrade
NULL -> Overweight
Reason
Barclays raised the firm's price target on Terns Pharmaceuticals to $27 from $14 and keeps an Overweight rating on the shares. The firm sys TERN-701 demonstrated a potentially best-in-class profile in chronic myeloid leukemia.
Terns Pharmaceuticals
William Blair
Market Perform -> Outperform
upgrade
2025-11-03
Reason
Terns Pharmaceuticals
William Blair
Price Target
2025-11-03
upgrade
Market Perform -> Outperform
Reason
William Blair upgraded Terns Pharmaceuticals to Outperform from Market Perform.
William Blair
Andy Hsieh
Market Perform -> Outperform
upgrade
2025-11-03
Reason
William Blair
Andy Hsieh
Price Target
2025-11-03
upgrade
Market Perform -> Outperform
Reason
As previously reported, William Blair analyst Andy Hsieh upgraded Terns Pharmaceuticals to Outperform from Market Perform after the company announced data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia. The overall major molecular response rate of 75%, with 64% achieving MMR by 24 weeks, is "impressive" and "topples investors expectations" and the competitive bar, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Terns Pharmaceuticals Inc (TERN.O) is -14.96, compared to its 5-year average forward P/E of -4.61. For a more detailed relative valuation and DCF analysis to assess Terns Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.61
Current PE
-14.96
Overvalued PE
-2.42
Undervalued PE
-6.80
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.71
Current EV/EBITDA
-10.55
Overvalued EV/EBITDA
1.23
Undervalued EV/EBITDA
-4.65
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10.77
Current PS
18.25
Overvalued PS
56.45
Undervalued PS
-34.90
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+7.23%
-27.38M
Operating Profit
FY2025Q2
YoY :
+5.97%
-24.09M
Net Income after Tax
FY2025Q2
YoY :
-16.13%
-0.26
EPS - Diluted
FY2025Q2
YoY :
+16.60%
-18.88M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 5858.69% over the last month.
Sold
0-3
Months
448.8K
USD
2
3-6
Months
3.6K
USD
1
6-9
Months
2.4K
USD
1
0-12
Months
211.1K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
4
186.6K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
110.5K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
2.3M
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
24.6K
Volume
Months
0-12
3
2.8M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 5858.69% over the last month.
Sold
0-3
Months
448.8K
USD
2
3-6
Months
3.6K
USD
1
6-9
Months
2.4K
USD
1
0-12
Months
211.1K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
4
186.6K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
110.5K
USD
Months
TERN News & Events
Events Timeline
2025-11-03 (ET)
2025-11-03
09:19:44
Terns Pharmaceuticals reveals findings from the CARDINAL trial of TERN-701.
2025-10-22 (ET)
2025-10-22
05:22:53
Terns Pharmaceuticals announces 12-week findings from TERN-601 study
2025-08-20 (ET)
2025-08-20
10:56:44
Mizuho: Terns Sees Opportunity in Underwhelming Competitor Oral GLP-1 Data
Sign Up For More Events
Sign Up For More Events
News
2.0
11-04BenzingaMajor Stocks on the Rise Tuesday: Henry Schein, Sanmina, Wingstop, Waters, and More
6.0
11-03BenzingaWilliam Blair Raises Terns Pharma Rating to Outperform
9.0
11-03BenzingaAnalyst Upgrades Terns Pharmaceuticals' Leukemia Drug, Highlighting Its Potential to Transform CML Treatment Landscape
Sign Up For More News
People Also Watch
AMPX
Amprius Technologies Inc
12.730
USD
+13.06%
JMIA
Jumia Technologies AG
10.890
USD
+5.01%
LND
BrasilAgro - Companhia Brasileira de Propriedades Agricolas
3.660
USD
-1.35%
HBCP
Home Bancorp Inc
53.830
USD
+0.75%
CYRX
Cryoport Inc
8.380
USD
+0.60%
HOUS
Anywhere Real Estate Inc
11.420
USD
+1.15%
ZEUS
Olympic Steel Inc
34.350
USD
-0.17%
NYXH
Nyxoah SA
4.917
USD
-2.05%
HLLY
Holley Inc
3.620
USD
+32.60%
FAQ
What is Terns Pharmaceuticals Inc (TERN) stock price today?
The current price of TERN is 18.47 USD — it has increased 1.21 % in the last trading day.
What is Terns Pharmaceuticals Inc (TERN)'s business?
What is the price predicton of TERN Stock?
What is Terns Pharmaceuticals Inc (TERN)'s revenue for the last quarter?
What is Terns Pharmaceuticals Inc (TERN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Terns Pharmaceuticals Inc (TERN)'s fundamentals?
How many employees does Terns Pharmaceuticals Inc (TERN). have?